Achilles Therapeutics plc

NasdaqCM ACHL

Achilles Therapeutics plc Shareholders' Equity for the year ending December 31, 2023: USD 142.37 M

Achilles Therapeutics plc Shareholders' Equity is USD 142.37 M for the year ending December 31, 2023, a -27.75% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Achilles Therapeutics plc Shareholders' Equity for the year ending December 31, 2022 was USD 197.04 M, a -31.94% change year over year.
Achilles Therapeutics plc Shareholders' Equity for the year ending December 31, 2021 was USD 289.53 M, a 52.89% change year over year.
Achilles Therapeutics plc Shareholders' Equity for the year ending December 31, 2020 was USD 189.37 M, a 86.85% change year over year.
Achilles Therapeutics plc Shareholders' Equity for the year ending December 31, 2019 was USD 101.35 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: ACHL

Achilles Therapeutics plc

CEO	Dr. Iraj Ali Ph.D.
IPO Date	March 31, 2021
Location	United Kingdom
Headquarters	245 Hammersmith Road
Employees	204
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years